The estimated Net Worth of International Holdings Ltd.... is at least $980 Tisíc dollars as of 9 July 2020. International Ltd owns over 71,753 units of Brainstorm Cell Therapeutics stock worth over $18,775 and over the last 14 years International sold BCLI stock worth over $960,773.
International has made over 11 trades of the Brainstorm Cell Therapeutics stock since 2011, according to the Form 4 filled with the SEC. Most recently International sold 71,753 units of BCLI stock worth $960,773 on 9 July 2020.
The largest trade International's ever made was buying 939,600 units of Brainstorm Cell Therapeutics stock on 28 April 2014 worth over $281,880. On average, International trades about 148,078 units every 304 days since 2011. As of 9 July 2020 International still owns at least 67,053 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of International Ltd stock trades at the bottom of the page.
International's mailing address filed with the SEC is MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA, D8, VG 1110.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger a International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: